Figure 5
Figure 5. BAFF promotes survival of CD27− B cells from patients with cGVHD. Frequency of live cells with or without BAFF measured by FSC and SSC in (A) CD27− or (B) CD27+ B cells from patients with cGVHD. (A) Left panel: Dot plots show the frequency of live CD27− B cells from a patient with cGVHD treated with media (44.4%) or BAFF (58.1%) for 48 hours. Right: Percent increase in live CD27− B cells in response to BAFF quantified at 24 and 48 hours. Data are median ± range from a single experiment; n = 3. *P = .009 (unpaired 2-tailed t test). (B) Left panel: Dot blots show the frequency of live CD27+ B cells from a patient with cGVHD treated with media (49.0%) or BAFF (51.1%) for 48 hours. Right: Percent increase in live CD27+ B cells in response to BAFF quantified at 24 and 48 hours. Data are median ± range from a single experiment; n = 3. Not significant, P = .53 (unpaired 2-tailed t test).

BAFF promotes survival of CD27− B cells from patients with cGVHD. Frequency of live cells with or without BAFF measured by FSC and SSC in (A) CD27− or (B) CD27+ B cells from patients with cGVHD. (A) Left panel: Dot plots show the frequency of live CD27− B cells from a patient with cGVHD treated with media (44.4%) or BAFF (58.1%) for 48 hours. Right: Percent increase in live CD27− B cells in response to BAFF quantified at 24 and 48 hours. Data are median ± range from a single experiment; n = 3. *P = .009 (unpaired 2-tailed t test). (B) Left panel: Dot blots show the frequency of live CD27+ B cells from a patient with cGVHD treated with media (49.0%) or BAFF (51.1%) for 48 hours. Right: Percent increase in live CD27+ B cells in response to BAFF quantified at 24 and 48 hours. Data are median ± range from a single experiment; n = 3. Not significant, P = .53 (unpaired 2-tailed t test).

Close Modal
This Feature Is Available To Subscribers Only

or Create an Account

Close Modal
Close Modal